AstraZeneca PLC (AZN)vsTiziana Life Sciences Ltd (TLSA)
AZN
AstraZeneca PLC
$157.24
-0.50%
HEALTHCARE · Cap: $243.86B
TLSA
Tiziana Life Sciences Ltd
$1.14
+9.13%
HEALTHCARE · Cap: $125.99M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates -1707082% more annual revenue ($61.37B vs $-3.60M). AZN leads profitability with a 17.0% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 65/100 (B-).
AZN
Strong Buy65
out of 100
Grade: B-
TLSA
Avoid16
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+20.4%
Fair Value
$196.68
Current Price
$157.24
$39.44 discount
Intrinsic value data unavailable for TLSA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
No standout strengths identified
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Trading at 14.2x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.40 suggests the stock is reasonably priced for its growth.
Bull Case : TLSA
TLSA has a balanced fundamental profile.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : TLSA
The primary concerns for TLSA are Price/Book, Revenue Growth, EPS Growth. Debt-to-equity of 8.77 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while TLSA is a value play — different risk/reward profiles.
TLSA carries more volatility with a beta of 0.46 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (65/100 vs 16/100), backed by strong 17.0% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Tiziana Life Sciences Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Tiziana Life Sciences Plc, a clinical-stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the UK.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?